Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.15 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (114 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | 47 Parkinson's trials, 2 stopped | 0.97 |
| literature PubMed | 13 Parkinson's papers of 421 | 0.65 |
| pathways Reactome | 6 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 2194
Sealed predictions
- NEFL in dopamine neurons, braak-0.21 (p 0.583) → +0.76 (p 0.018)receipt 2200
Swarm cases
receipt 2200: NEFL in dopamine neurons, braak
- power
- full sample +0.23 (p 0.365, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.341, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.332, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.42, sign flips 0; without severely affected donors +0.23 (p 0.365, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NEFL in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts